STAT

NOVEMBER 25, 2024

UnitedHealth Group is paying many of its own physician practices significantly more than it pays other doctor groups in the same markets for similar services, undermining competition and driving up costs for consumers and businesses, a STAT investigation reveals.   The findings, drawn from a sample of practices across the country, expose the effects of a deepening conflict of interest: Rather than use its size and market power to drive down the cost of care, UnitedHealth, as the corpor

Insurance 121

Insurance 121

Drug Topics

NOVEMBER 25, 2024

Benjamin Jolley, PharmD, pharmacist at Jolley’s Compounding Pharmacy in Salt Lake City, Utah, joined Drug Topics to discuss his career journey.

Compounding Pharmacies 98

Compounding Pharmacies Compounding 98

STAT

NOVEMBER 25, 2024

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more than a placebo in a large clinical trial.  The negative outcome is devastating for the nearly 2,000 participants in this study and a second study also shut down Monday.

94

94

Drug Topics

NOVEMBER 25, 2024

Tom Utech, PharmD, CEO of iA, joined Drug Topics to discuss his company’s centralized pharmacy fulfillment solutions.

98

98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

NOVEMBER 25, 2024

Should Robert F. Kennedy Jr. be confirmed as secretary of Health and Human Services, it will bring real political power to the network of wellness influencers who populate the Make America Health Again movement. Physicians like me are alarmed about many of Kennedy’s views on health. His anti-vaccination positions and his calls to prosecute medical journals, among other dangerous views, should never be normalized, are disqualifying for the position he seeks, and threaten to beat back decad

Vaccines 78

Vaccines 78

Fierce Pharma

NOVEMBER 25, 2024

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los | The FDA has signed off on BridgeBio's Attruby (acoramidis), a potential blockbuster to treat patients with the rare heart disease transthyretin amyloid cardiomyopathy.

FDA 77

FDA 77

STAT

NOVEMBER 25, 2024

Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of the leading dark horse approaches to treating the neurodegenerative disease. The drug, called AL002, is designed to activate a group of surveilling neuronal immune cells called microglia. It was among several efforts, now in or nearing clinical trials, predicated on the notion that modulating the brain’s immune system could slow the degener

Immunization 72

Immunization 72

Pharmacy Times

NOVEMBER 25, 2024

Findings highlight the unmet medical need for outpatient interventions and preventive measures that can reduce hospitalizations.

Hospitals 81

Hospitals 81

Drug Topics

NOVEMBER 25, 2024

A number of new, nonopioid osteoarthritis treatment options are either available for patients or in the development pipeline.

76

76

pharmaphorum

NOVEMBER 25, 2024

IT industry group techUK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care.

79

79

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

NOVEMBER 25, 2024

Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple

65

65

Fierce Pharma

NOVEMBER 25, 2024

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. | In the phase 3 ZENITH study, Merck’s activin signaling inhibitor Winrevair met its primary endpoint of time to first morbidity or mortality event, which included all-cause death, lung transplantation, or hospitalization for at least 24 hours linked to disease worsening in patients with PAH.

Hospitals 71

Hospitals FDA 71

Pharmacy Times

NOVEMBER 25, 2024

Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.

65

65

Fierce Pharma

NOVEMBER 25, 2024

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol Myers Squibb's Revlimid and Roche's Rituxan—triggered a 57% reduction in the risk of disease progression, relapse or death in R/R FL patients compared with those who were treated with placebo, Revlimid and Rituxan.

FDA 70

FDA 70

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

NOVEMBER 25, 2024

Jai N. Patel, PharmD, BCOP, CPP, discussed efforts to standardize the evaluation of clinical utility in pharmacogenetics, emphasizing its variability, the role of pharmacogenomics in research, and the importance of robust study designs for pharmacy professionals.

65

65

Fierce Pharma

NOVEMBER 25, 2024

Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification (WARN) update.

70

70

Fierce Healthcare

NOVEMBER 25, 2024

UnitedHealthcare successfully won its lawsuit over the Centers for Medicare and Medicaid Services, a federal judge determined Nov. 22. | UnitedHealthcare will get to claim victory over CMS for its star ratings lawsuit win. The insurer will receive a recalculated score from the federal agency, potentially giving the insurer more in quality bonus payments.

Insurance 69

Insurance 69

STAT

NOVEMBER 25, 2024

Minnesota hospitals participating in a controversial U.S. drug discount program reaped at least $630 million in revenue last year and the largest institutions were the biggest beneficiaries, according to a report from the Minnesota Department of Health. Specifically, hospitals received $1.5 billion in discounted medicines under the 340B Drug Discount program, but paid $734 million plus another $120 million to various parties for administration fees.

Hospitals 69

Hospitals 69

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

NOVEMBER 25, 2024

Atlanta-based Emory Healthcare is looking to scale up its population health management efforts, expanding primary care to hundreds of thousands of patients across Georgia, and tapped health tech co | Atlanta-based Emory Healthcare is looking to scale up its population health management efforts, expanding primary care to hundreds of thousands of patients across Georgia, and tapped health tech company Guidehealth to turbocharge its work.

64

64

Fierce Pharma

NOVEMBER 25, 2024

After a recent failed showing in a breast cancer subgroup raised doubts around AstraZeneca’s Truqap, the first-in-class AKT inhibitor is making inroads in a prostate cancer subtype. | The AKT inhibitor's early win in a prostate cancer subtype follows a recent surprise flop in a breast cancer study. AZ has been working to grow Truqap beyond its current limited approval in a niche breast cancer category.

62

62

Drug Topics

NOVEMBER 25, 2024

This approval marks the availability of the first near-complete stabilizer of transthyretin.

FDA 76

FDA 76

Pharmacy Times

NOVEMBER 25, 2024

Expert discussed benefits of precision oncology treatments that utilize thousands of biomarkers to design personalized treatment plans.

65

65

pharmaphorum

NOVEMBER 25, 2024

After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer.

74

74

Pharmacy Times

NOVEMBER 25, 2024

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

FDA 73

FDA 73

Fierce Healthcare

NOVEMBER 25, 2024

Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would benefit from the drugs. | Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would benefit from the drugs.

59

59

Pharmafile

NOVEMBER 25, 2024

Langland, a medical life sciences company with focuses on areas surrounding Clinical Trial experience, Medical Strategy and Education, Public Relations and Engagement and Advertising, has announced the appointment of Gemma Cathcart as managing partner for the Advertising sector. Gemma, who has held previous roles such as managing partner of Global Health from Avalere Health and […] The post Gemma Cathcart appointed managing partner at Langland appeared first on Pharmafile.

59

59

pharmaphorum

NOVEMBER 25, 2024

Watch this exclusive interview with health innovators Lori Fletcher and Amber Beimer from Advanced Clinical as they discuss the latest trends and advancements in the Functional Service Provider (FSP) field.

59

59

PharmaVoice

NOVEMBER 25, 2024

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although he describes himself as pro-vaccine.

FDA 59

FDA Vaccines 59

Pharmacy Times

NOVEMBER 25, 2024

Community health care workers help support both primary care and school settings by assisting with medication administration and communications with staff.

Communication 81

Communication 81

pharmaphorum

NOVEMBER 25, 2024

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations.

64

64

Pharmaceutical Commerce

NOVEMBER 25, 2024

In the second part of this roundtable discussion, key opinion leaders discuss the potential technological challenges surrounding RFID, and the likelihood of not only utilizing this tech at the item level but for product security purposes as well.

52

52

The Checkup by Singlecare

NOVEMBER 25, 2024

Entresto tablets contain two drugs: valsartan and sacubitril. This combination allows your heart to pump blood more efficiently, managing certain types of heart failure in adults and children older than 1, and helping to lower the risk of death and hospitalization. Entresto belongs to a class of drugs called angiotensin receptor neprilysin inhibitors ( ARNIs ).

Dosage 52

Dosage Hospitals FDA 52

European Pharmaceutical Review

NOVEMBER 25, 2024

The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. Ltd. Their analysis projected that the market will exceed a value of $15.46 billion by 2032. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3 percent between 2024 and 2032.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52